Study M764
Study name | Hoda U 2021 |
Title | Embelin ameliorates cognitive dysfunction and progression of kindling in pentylenetetrazol-induced kindling in mice by attenuating brain inflammation |
Overall design | The aim of this study was to evaluate the effect of embelin on various epileptic models and related brain inflammation. Swiss albino mice were divided into the following 4 groups: (1) control group, (2) pentylenetetrazol group, (3) pentylenetetrazol + middle dose of embelin group (pentylenetetrazol plus embelin treatment at the dose of 10 mg/kg), and (4) pentylenetetrazol + high dose of embelin group (pentylenetetrazol plus embelin treatment at the dose of 20 mg/kg). Embelin was administrated per orally in addition to alternate-day pentylenetetrazol 60 mg/kg i.p. for 5 weeks. Administration of pentylenetetrazol to the animals in the chronic study for 5 weeks caused depressive-like behavior, and embelin could alleviating depressive-like behavior. Levels of neurotransmitters (GABA, glutamate, and dopamine) in the hippocampus and cortex were measured (n = 8 per group). |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Mouse; Swiss albino mouse; |
Categories of depression | Animal model; Other animal model; Other animal model; |
Criteria for depression | Forced swimming test |
Sample size | 32 |
Tissue | Central; Brain; Cortex; Central; Brain; Hippocampus; |
Platform | MS-based; LC-MS: Finnigan Surveyor UHPLC with online degasser and PDA detector coupled with ABI 4000 Q Trap mass spectrometer (Applied Biosystems, USA); |
PMID | |
DOI | |
Citation | Hoda U, Jain S, Samim M, et al. Embelin ameliorates cognitive dysfunction and progression of kindling in pentylenetetrazol-induced kindling in mice by attenuating brain inflammation. Epilepsy Behav. 2021 Mar;116:107788. |
Metabolite |
